A new era
of Allogeneic
T-Cell Therapies
Pipeline
PROGRAM
INDICATIONS
DISCOVERY
PRE-CLINICAL
PHASE 1
PIVOTAL
CAR-T (Allogeneic)
T-ALL/LBL
T-NHL
Autoimmune indications
T-ALL = T-cell Acute Lymphoblastic Leukemia
T-LBL = T-cell Lymphoblastic Lymphoma
T-NHL = T-cell Non-Hodgkin’s Lymphoma
AML = Acute Myeloid Leukemia
Latest News
Additional capital brings total raised to $150 million in a
Relapsed/refractory T-cell acute lymphoblastic leukemia (ALL; T-ALL)/lymphoma (LBL) represent a
FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot